This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D81.2 | Synonyms: T-B+NK- SCID, T-B+NK+ SCID, γc-SCID, JAK3 deficiency SCID, IL-7Rα deficiency SCID, X-linked severe combined immunodeficiency (X-SCID)
Forms of SCID in which B cells are normal or elevated despite T-cell deficiency were already recognized clinically in the 1960s–70s. In particular, attention was drawn to the fact that SCID showing an X-linked mode of inheritance occurs only in boys, and this was named X-linked severe combined immunodeficiency (X-SCID).
In 1993, Noguchi et al. showed that X-SCID is caused by mutations in the interleukin-2 receptor gamma chain (IL2RG, γc) gene located on the X chromosome. It was subsequently established that γc is the common gamma chain of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors and is essential for signaling by multiple cytokines.
In 1995, Macchi et al. reported that JAK3 deficiency, a kinase linked to γc, causes autosomal recessive SCID. In the same year, Puel et al. discovered that IL-7Rα (IL7R gene) deficiency causes T-B+NK+ SCID.
In 2000, Fischer's team succeeded in γc gene therapy using a retroviral vector in X-SCID patients, reporting the world's first successful clinical case of gene therapy. However, T-cell leukemia due to insertional mutagenesis subsequently developed in some patients, raising major challenges regarding vector safety.
Mutations in the IL2RG gene (Xq13.1) located on the X chromosome are the most common cause, accounting for about 40–50% of all SCID. The γc protein functions as the common gamma chain of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors.
Mutations in the JAK3 gene (19p13.1) are inherited in an autosomal recessive manner and show a T-B+NK- phenotype similar to γc. JAK3 binds to γc and transmits cytokine signals to the JAK-STAT pathway.
IL-7Rα (IL7R gene, 5p13.2) deficiency causes T-B+NK+ SCID. IL-7 is essential for T-cell development, but IL-15 is more important for NK-cell development, so NK cells are preserved.
Various causes, such as defects in CD45 (PTPRC), CD3δ, CD3ε, CD3ζ, and CD3γ, can cause SCID with a T-B+ phenotype.
X-SCID due to IL2RG mutations follows X-linked recessive inheritance. When the mother is a carrier, 50% of sons are affected. Female heterozygous carriers are normal, but very rarely symptoms may appear when there is skewed X-inactivation.
JAK3 and IL7R defects are autosomal recessive and affect males and females equally.
Partial loss-of-function variants of IL2RG can show various phenotypes milder than complete SCID, such as combined immunodeficiency (CID), Omenn syndrome, and DiGeorge-like syndrome.
D81.2 (T-B+NK+ or T-B+NK- SCID) includes the most common types of all SCID. X-SCID alone accounts for about 40–50% of all SCID. The overall incidence of SCID is 1/50,000–1/100,000 newborns.
Because X-SCID occurs only in boys, in populations where X-SCID predominates, the proportion of boys among all SCID patients is high (about 2:1–3:1). JAK3 and IL7R defects occur equally in males and females.
In Korea, T-B+ types of SCID, including X-SCID, are reported under the D81.2 classification. There are a small number of confirmed cases at tertiary medical institutions such as Seoul National University Children's Hospital, and accurate national data are lacking.
γc is the common signaling subunit of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors. γc binds JAK3 and, upon cytokine binding, activates the JAK-STAT signaling pathway, which activates transcription factors such as STAT5 and STAT3. In γc or JAK3 deficiency, signaling by all of these cytokines is blocked.
Blockade of IL-7 signaling makes proliferation and survival of T progenitor cells in the thymus impossible, so T-cell development is almost completely blocked. Blockade of IL-15 signaling also blocks NK-cell development (γc/JAK3 defects with the T-B+NK- phenotype). In IL-7Rα deficiency, only IL-7 signaling is blocked, so T cells are deficient but NK cells develop normally via IL-15 signaling (T-B+NK+ phenotype).
Because B cells have no direct impairment of V(D)J recombination, they are present in normal or increased numbers, but they cannot mount functional antibody responses owing to the lack of T-cell help.
After 3–6 months of age, pneumonia, chronic diarrhea, oral candidiasis, skin infections, sepsis, etc. recur. Disseminated BCG infection after BCG vaccination may occur and can provide a clue to the diagnosis. Pneumocystis jirovecii pneumonia (PCP) is frequent and fatal.
Weight loss, failure to thrive, and developmental delay due to recurrent infections accompany.
In some patients, engraftment of maternal T cells in the fetus during pregnancy (maternal-fetal graft-versus-host reaction) can cause skin rash, liver function abnormalities, and cytopenias.
Underdeveloped tonsils, nonpalpable lymph nodes, absent thymic shadow on chest radiography. Findings of severe failure to thrive and malnutrition are common.
CBC shows a decreased absolute lymphocyte count (especially decreased T cells). Flow cytometry shows markedly decreased T cells (CD3+), normal or increased B cells (CD19+), and decreased NK cells (γc/JAK3 defects) or normal NK cells (IL7R defect). Serum IgG, IgA, and IgM are decreased (after 6 months of age).
T-cell proliferative responses to mitogens such as PHA and ConA are markedly reduced or absent.
Because of T-cell deficiency, TRECs are extremely low or undetectable. Both X-SCID and JAK3/IL7R deficiency SCID show a positive result on TREC screening.
When there is a family history, prenatal diagnosis is made during pregnancy by maternal serum genetic testing (cell-free DNA) or by IL2RG gene analysis after CVS/amniocentesis.
Flow cytometry confirms a T-B+NK- or T-B+NK+ phenotype. T-B+NK- phenotype → suspect IL2RG or JAK3 defect. T-B+NK+ phenotype → suspect IL7R, CD3 chain, or CD45 defect.
IL2RG sequencing (confirmation of X-SCID), JAK3 and IL7R gene analysis. If the standard gene panel is negative, whole exome sequencing (WES) is performed.
Confirming loss of γc (CD132) protein expression by Western blot or flow cytometry aids rapid diagnosis.
HSCT is the standard curative treatment. With early transplantation (before 3.5 months of age, in an infection-free state), a survival rate of 90% or more can be expected. In X-SCID, T-cell and NK-cell reconstitution after HSCT is excellent, but when B-cell reconstitution is incomplete, long-term IVIG is needed.
X-SCID is one of the most successful models of gene therapy. Clinical trials of IL2RG gene therapy using self-inactivating (SIN) lentiviral vectors are under way in the United States (UCSF), the United Kingdom (UCL), France (Paris), and elsewhere, and early results are promising.
Protective isolation, IVIG, antibacterial·antifungal·antiviral prophylaxis. No BCG vaccination, no live vaccines. Use of CMV-negative irradiated blood.
In patients who underwent HSCT before infections occurred through newborn screening, survival at 10 years or more exceeds 90%. When infections are present, the prognosis is markedly poor.
In clinical trials of SIN lentiviral gene therapy, 90% or more of patients showed T-cell reconstitution and clinical improvement.
Incomplete immune reconstitution after HSCT, chronic graft-versus-host disease (cGvHD), growth problems, etc. are issues for long-term follow-up.
Nationwide expansion of TREC-based newborn screening aims at early diagnosis and HSCT before infections occur.
In high-risk pregnancies with a family history, prenatal genetic diagnosis and planning of HSCT before delivery are important.
No live vaccines (BCG, MMR, varicella, etc.), PCP prophylaxis, IVIG supplementation, protective isolation. In families with a sibling with SCID, the newborn is isolated immediately and genetic testing is performed.